GENETIC POLYMORPHISM OF SOD2 AND GPX1 MODIFY OXIDATIVE STRESS BIOMARKERS IN AN IRANIAN POPULATION WITH CHRONIC KIDNEY DISEASE

Main Article Content

Muslim Jassim
Gholamreza Dehghan
Hamid Tayebi Khosroshahi
Mehdi Haghi

Keywords

Chronic kidney disease, SOD2, GPX1, Gene polymorphism, Oxidative damage

Abstract

This work aimed to investigate the association between superoxide dismutase 2 (SOD2) and glutathione peroxidase 1 (GPX1) gene single nucleotide polymorphisms (SNPs) in chronic kidney disease (CKD) patients and their influence on the serum level of oxidative biomarkers, including protein thiol and carbonyl groups (PTGs and PCGs), advanced oxidative protein products (AOPPs), nitrotyrosine, malondialdehyde (MDA), malondialdehyde adducts (MDA adducts), total oxidant status (TOS) and prooxidant-antioxidant balance (PAB). For this purpose, blood samples were obtained from 50 CKD patients with a mean age of 70.65±4.85 years. Real-time polymerase chain reaction was used for genotyping. Byproducts of oxidative stress were analyzed by ELISA and UV spectroscopic or calorimetric methods. The obtained results indicated that the risk of CKD development in subjects with the GPX1 Lue/Lue genotype increased (OR=1.67, p<0.05), which was considerably greater in people with the combination of SOD2 Val/Val/GPX1 Leu/Leu genotype (OR=1.92, p<0.05). Our results showed that the concentration of MDA, PTG, PCG, and BAP was increased in subjects carrying the SOD2 Val/Val genotype. Also, the findings revealed that individuals with the GPX1 Lue/Lue genotype showed higher levels of MDA, MDA adducts, PTG, and nitrotyrosine in the serum. Our findings supported the hypothesis that the genotypes SOD2 Val/Val and GPX1 Leu/Leu greatly enhance the risk of CKD.

Abstract 111 | PDF Downloads 68

References

[1] T. K. Chen, D. H. Knicely, and M. E. Grams, "Chronic kidney disease diagnosis and management: a review," Jama, vol. 322, no. 13, pp. 1294-1304, 2019.
[2] M. Ghelichi-Ghojogh, M. Fararouei, M. Seif, and M. Pakfetrat, "Chronic kidney disease and its health-related factors: a case-control study," BMC nephrology, vol. 23, no. 1, pp. 1-7, 2022.
[3] A. Klisic, N. Kavaric, A. Ninic, and J. Kotur-Stevuljevic, "Oxidative stress and cardiometabolic biomarkers in patients with non-alcoholic fatty liver disease," Scientific Reports, vol. 11, no. 1, p. 18455, 2021.
[4] T.-J. Lee, S. K. Nettleford, A. McGlynn, B. A. Carlson, G. S. Kirimanjeswara, and K. S. Prabhu, "The role of selenoproteins in neutrophils during inflammation," Archives of Biochemistry and Biophysics, vol. 732, p. 109452, 2022.
[5] Z. Corredor et al., "Genetic variants associated with chronic kidney disease in a Spanish population," Scientific Reports, vol. 10, no. 1, p. 144, 2020.
[6] R. A. Abd El Azeem, M. M. Zedan, E. A. Saad, T. M. Mutawi, and Z. R. Attia, "Single-nucleotide polymorphisms (SNPs) of antioxidant enzymes SOD2 and GSTP1 genes and SLE risk and severity in an Egyptian pediatric population," Clinical Biochemistry, vol. 88, pp. 37-42, 2021.
[7] B. Álvarez-González et al., "Genetic variants of antioxidant and xenobiotic metabolizing enzymes and their association with prostate cancer: A meta-analysis and functional in silico analysis," Science of The Total Environment, p. 165530, 2023.
[8] V. L. Kinnula and J. D. Crapo, "Superoxide dismutases in malignant cells and human tumors," Free Radical Biology and Medicine, vol. 36, no. 6, pp. 718-744, 2004.
[9] D. P. Cronin-Fenton et al., "Manganese superoxide dismutase and breast cancer recurrence: a Danish clinical registry-based case-control study, and a meta-analysis," PLoS One, vol. 9, no. 1, p. e87450, 2014.
[10] Z. Corredor et al., "Loci associated with genomic damage levels in chronic kidney disease patients and controls," Mutation Research/Genetic Toxicology and Environmental Mutagenesis, vol. 852, p. 503167, 2020.
[11] B. Dragicevic et al., "Association of SOD2 (Rs4880) and GPX1 (rs1050450) gene polymorphisms with risk of Balkan endemic nephropathy and its related tumors," Medicina, vol. 55, no. 8, p. 435, 2019.
[12] M. Aung, T. Konoshita, J. Moodley, T. Naicker, C. Connolly, O.P. Khaliq, P. Gathiram, Aminopeptidase A (ENPEP) gene polymorphisms and preeclampsia: Descriptive analysis, European Journal of Obstetrics & Gynecology and Reproductive Biology, vol. 258, p. 70-74, 2021.
[13] D. A. Martínez-Treviño et al., "Rapid Detection of the GSTM3 A/B polymorphism using real-time PCR with TaqMan® Probes," Archives of medical research, vol. 47, no. 2, pp. 142-145, 2016.
[14] M. Bošković et al., "Association of SOD2, GPX1, CAT, and TNF genetic polymorphisms with oxidative stress, neurochemistry, psychopathology, and extrapyramidal symptoms in schizophrenia," Neurochemical Research, vol. 38, pp. 433-442, 2013.
[15] P. Vats, N. Sagar, T. Singh, and M. Banerjee, "Association of Superoxide dismutases (SOD1 and SOD2) and Glutathione peroxidase 1 (GPx1) gene polymorphisms with type 2 diabetes mellitus," Free radical research, vol. 49, no. 1, pp. 17-24, 2015.
[16] Y. J. Garcia, A. J. Rodríguez-Malaver, and N. Peñaloza, "Lipid peroxidation measurement by thiobarbituric acid assay in rat cerebellar slices," Journal of Neuroscience Methods, vol. 144, no. 1, pp. 127-135, 2005.
[17] O. Erel, "A new automated colorimetric method for measuring total oxidant status," Clinical biochemistry, vol. 38, no. 12, pp. 1103-1111, 2005.
[18] D. H. Alamdari, K. Paletas, T. Pegiou, M. Sarigianni, C. Befani, and G. Koliakos, "A novel assay for the evaluation of the prooxidant–antioxidant balance, before and after antioxidant vitamin administration in type II diabetes patients," Clinical biochemistry, vol. 40, no. 3-4, pp. 248-254, 2007.
[19] M. Gyurászová, R. Gurecká, J. Bábíčková, and Ľ. Tóthová, "Oxidative stress in the pathophysiology of kidney disease: Implications for noninvasive monitoring and identification of biomarkers," Oxidative Medicine and Cellular Longevity, vol. 2020, 54787082020, 2020.
[20] Csaba P. Kovesdy, "Epidemiology of chronic kidney disease: an update 2022," Kidney International Supplements, vol 12, no1, p 7-11, 2022.
[21] D. E. Weiner et al., "The Framingham predictive instrument in chronic kidney disease," Journal of the American College of Cardiology, vol. 50, no. 3, pp. 217-224, 2007.
[22] A. Podkowińska and D. Formanowicz, "Chronic kidney disease as oxidative stress-and inflammatory-mediated cardiovascular disease," Antioxidants, vol. 9, no. 8, p. 752, 2020.
[23] Y. Souiden et al., "MnSOD and GPx1 polymorphism relationship with coronary heart disease risk and severity," Biological research, vol. 49, no. 1, pp. 1-12, 2016.
[24] A. Crawford et al., "Glutathione peroxidase, superoxide dismutase and catalase genotypes and activities and the progression of chronic kidney disease," Nephrology Dialysis Transplantation, vol. 26, no. 9, pp. 2806-2813, 2011.
[25] S. Mihailovic et al., "The association of polymorphisms in Nrf2 and genes involved in Redox Homeostasis in the Development and Progression of Clear Cell Renal Cell Carcinoma," Oxidative Medicine and Cellular Longevity, vol. 2021, 2021.
[26] K. Mohammedi et al., "Manganese superoxide dismutase (SOD2) polymorphisms, plasma advanced oxidation protein products (AOPP) concentration and risk of kidney complications in subjects with type 1 diabetes," PloS one, vol. 9, no. 5, p. e96916, 2014.
[27] A. Crawford et al., "Relationships between single nucleotide polymorphisms of antioxidant enzymes and disease," Gene, vol. 501, no. 2, pp. 89-103, 2012.
[28] A. Sutton, H. Khoury, C. Prip-Buus, C. Cepanec, D. Pessayre, and F. Degoul, "The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria," Pharmacogenetics and Genomics, vol. 13, no. 3, pp. 145-157, 2003.
[29] A. Sutton et al., "The manganese superoxide dismutase Ala16Val dimorphism modulates both mitochondrial import and mRNA stability," Pharmacogenetics and genomics, vol. 15, no. 5, pp. 311-319, 2005.
[30] C.-T. Chao et al., "Interplay between superoxide dismutase, glutathione peroxidase, and peroxisome proliferator activated receptor gamma polymorphisms on the risk of end-stage renal disease among Han Chinese patients," Oxidative Medicine and Cellular Longevity, vol. 2016, 2016.
[31] H. Fujimoto et al., "Manganese superoxide dismutase polymorphism affects the oxidized low-density lipoprotein-induced apoptosis of macrophages and coronary artery disease," European Heart Journal, vol. 29, no. 10, pp. 1267-1274, 2008.
[32] T. Zheikova et al., "Glutathione peroxidase 1 (GPX1) single nucleotide polymorphism Pro198→ Leu: Association with life span and coronary artery disease," Molecular Biology, vol. 46, pp. 433-437, 2012.
[33] J. M. Marzec et al., "Functional polymorphisms in the transcription factor NRF2 in humans increase the risk of acute lung injury," The FASEB Journal, vol. 21, no. 9, pp. 2237-2246, 2007.
[34] A. A. Adwas, A. Elsayed, A. Azab, and F. Quwaydir, "Oxidative stress and antioxidant mechanisms in human body," J. Appl. Biotechnol. Bioeng, vol. 6, no. 1, pp. 43-47, 2019.
[35] S.-Y. Shim and H.-S. Kim, "Oxidative stress and the antioxidant enzyme system in the developing brain," Korean Journal of Pediatrics, vol. 56, no. 3, p. 107, 2013.
[36] Y. Shimoyama, Y. Mitsuda, Y. Tsuruta, N. Hamajima, and T. Niwa, "Polymorphism of Nrf2, an antioxidative gene, is associated with blood pressure and cardiovascular mortality in hemodialysis patients," International Journal of Medical Sciences, vol. 11, no. 7, p. 726, 2014.
[37] T. Nomiyama et al., "The polymorphism of manganese superoxide dismutase is associated with diabetic nephropathy in Japanese type 2 diabetic patients," Journal of Human Genetics, vol. 48, no. 3, pp. 138-141, 2003.
[38] A. Mollsten et al., "A functional polymorphism in the manganese superoxide dismutase gene and diabetic nephropathy," Diabetes, vol. 56, no. 1, pp. 265-269, 2007.
[39] A. Möllsten, A. Jorsal, M. Lajer, N. Vionnet, and L. Tarnow, "The V16A polymorphism in SOD2 is associated with increased risk of diabetic nephropathy and cardiovascular disease in type 1 diabetes," Diabetologia, vol. 52, pp. 2590-2593, 2009.
[40] M. A. El-Far, M. A. Bakr, S. E. Farahat, and E. A. A. El-Fattah, "Glutathione peroxidase activity in patients with renal disorders," Clinical and experimental nephrology, vol. 9, pp. 127-131, 2005.
[41] F. Bulucu, A. Vural, A. Aydin, and A. Sayal, "Oxidative stress status in adults with nephrotic syndrome," Clinical nephrology, vol. 53, no. 3, pp. 169-173, 2000.
[42] B. A. Zachara et al., "Selenium supplementation on plasma glutathione peroxidase activity in patients with end-stage chronic renal failure," Biological trace element research, vol. 97, pp. 15-30, 2004.
[43] B. A. Zachara, A. Salak, D. Koterska, J. Manitius, and W. Wasowicz, "Selenium and glutathione peroxidases in blood of patients with different stages of chronic renal failure," Journal of Trace Elements in Medicine and Biology, vol. 17, no. 4, pp. 291-299, 2004.

Most read articles by the same author(s)